Suppr超能文献

微小 RNA 作为肺肿瘤细胞中酪氨酸激酶抑制剂耐药性的关键调节因子。

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.

机构信息

Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Cell Commun Signal. 2022 Mar 9;20(1):27. doi: 10.1186/s12964-022-00840-4.

Abstract

Lung cancer is the second most common and the leading cause of cancer related deaths globally. Tyrosine Kinase Inhibitors (TKIs) are among the common therapeutic strategies in lung cancer patients, however the treatment process fails in a wide range of patients due to TKIs resistance. Given that the use of anti-cancer drugs can always have side effects on normal tissues, predicting the TKI responses can provide an efficient therapeutic strategy. Therefore, it is required to clarify the molecular mechanisms of TKIs resistance in lung cancer patients. MicroRNAs (miRNAs) are involved in regulation of various pathophysiological cellular processes. In the present review, we discussed the miRNAs that have been associated with TKIs responses in lung cancer. MiRNAs mainly exert their role on TKIs response through regulation of Tyrosine Kinase Receptors (TKRs) and down-stream signaling pathways. This review paves the way for introducing a panel of miRNAs for the prediction of TKIs responses in lung cancer patients. Video Abstract.

摘要

肺癌是全球第二大常见癌症,也是癌症相关死亡的主要原因。酪氨酸激酶抑制剂 (TKI) 是肺癌患者常见的治疗策略之一,但由于 TKI 耐药性,该治疗过程在广泛的患者中失败。鉴于抗癌药物的使用总会对正常组织产生副作用,因此预测 TKI 反应可以提供一种有效的治疗策略。因此,有必要阐明肺癌患者 TKI 耐药的分子机制。microRNAs (miRNAs) 参与调节各种病理生理细胞过程。在本综述中,我们讨论了与肺癌 TKI 反应相关的 miRNAs。miRNAs 主要通过调节酪氨酸激酶受体 (TKRs) 和下游信号通路来发挥其对 TKI 反应的作用。本综述为引入一组 miRNA 来预测肺癌患者的 TKI 反应铺平了道路。视频摘要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6f6/8905758/974662c6ee2d/12964_2022_840_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验